SynthesisJAMA internal medicine2020

Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Sean A Woolen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.